Archives
Lecanemab – a potential new treatment for Alzheimer’s disease
28 September 2022
![](https://news.joindementiaresearch.nihr.ac.uk/wp-content/uploads/2022/09/GettyImages-650160957-150x150.jpg)
News that a potential treatment for early stage Alzheimer’s disease can slow cognitive decline is a significant development in dementia research. About the drug Lecanemab is an antibody that is designed to remove toxic beta-amyloid deposits; proteins that build up in the brains of people with Alzheimer’s disease. Following phase 3 clinical trials, pharmaceutical companies […]
The non-approval of aducanumab in Europe still marks a significant stride forward in dementia research
17 December 2021
![](https://news.joindementiaresearch.nihr.ac.uk/wp-content/uploads/2021/12/JOB-head-and-shoulders_2019-150x150.png)
An opinion piece by Professor John O’Brien, NIHR Clinical Research Network National Specialty Lead for Dementias The European Medicines Agency (EMA) has today said no to approving aducanumab – a new drug to treat Alzheimer’s disease. EMA considered that although the drug removed amyloid, a toxic protein that builds up in the brains of people […]